Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics' stock (CVKD) has experienced significant fluctuations in the past six months. From January 10, 2025, to January 9, 2026, the share price declined by approximately 49.78%, from $16.27 to $8.17 per share. However, the company's shares surged by 11.6% in the week leading up to January 12, 2026, due to highlighting the potential of VLX-1005. Insider selling has also been noted, with company insiders selling more of their stock than they have bought in the past three months, totaling $204,630.00 in sales.

There is no readily available information to suggest significant demand seasonality for Cadrenal Therapeutics, Inc.'s products or services. The demand for such specialized therapeutics is typically driven by medical need and clinical development milestones rather than seasonal patterns.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare cardiovascular conditions, with its primary investigational product being Tecarfarin, a novel oral and reversible anticoagulant. Tecarfarin is being developed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. In December 2025, Cadrenal Therapeutics acquired VLX-1005, a first-in-class Phase 2 12-lipoxygenase (12-LOX) inhibitor, which is being developed for the treatment of heparin-induced thrombocytopenia (HIT).

Cadrenal Therapeutics, Inc. is a U.S.-based company with its headquarters located in Ponte Vedra, Florida.

Cadrenal Therapeutics has maintained a "Hold" consensus rating from analysts in the past year, with an average score of 2.00. MarketBeat's MarketRank™ scored Cadrenal Therapeutics higher than 67% of evaluated companies, ranking it 223rd out of 914 stocks in the medical sector. Recent positive developments include the acquisition of VLX-1005 in December 2025 and the subsequent highlighting of its potential for treating heparin-induced thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference in January 2026.

The ownership structure of Cadrenal Therapeutics, Inc. (CVKD) is a mix of institutional, insider, and retail investors. Approximately 5.50% of the company's stock is held by institutional shareholders, 53.11% by insiders, and 41.38% by retail investors. The largest individual shareholder is John Raymond Murphy, who owns 614,792 shares, representing 29.62% of the company.